
POAI Stock Forecast & Price Target
POAI Analyst Ratings
Bulls say
Predictive Oncology Inc. is on a growth trajectory, with projected risk-adjusted total revenues set to escalate from $1.5 million in 2024 to $48 million by 2033, reflecting a substantial compound annual growth rate (CAGR) of approximately 20%. The firm anticipates its first risk-adjusted collaboration revenues, primarily from its PEDAL-related preclinical programs, to reach around $9 million in 2025, with expectations of continued revenue growth across its segments. Additionally, the company's impressive advancements in enhancing protein solubility for clients further strengthen its competitive position within the healthcare sector, positioning it favorably for future growth and partnerships.
Bears say
Predictive Oncology Inc reported a net loss of $3.2 million, equivalent to $0.68 per share, for the second quarter of 2024, indicating ongoing financial distress. The company's ability to generate future revenues is jeopardized by potential failures in meeting the expectations of collaborative partners, as well as challenges in obtaining necessary regulatory approvals. Additionally, the recorded impairment of goodwill suggests underlying issues that could further dilute shareholder value and raises concerns about the sustainability of its operations.
This aggregate rating is based on analysts' research of Predictive Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
POAI Analyst Forecast & Price Prediction
Start investing in POAI
Order type
Buy in
Order amount
Est. shares
0 shares